Clinical Ink: acquisition by GI Partners
Clinical trial technology firm Clinical Ink has been acquired by private equity investment company GI Partners. Clinical Ink’s management team also invested in the transaction, and current investor NovaQuest will continue as a minority investor.
According to Clinical Ink CEO Ed Seguine, the investment will enable the company to expand its reach and accelerate its business model during a particularly challenging time.
“GI Partners’ acquisition is a powerful validation of our eSource vision for clinical trials and will add to our growing momentum in the marketplace,” he said. “I’m excited to work with GI Partners as we launch our latest innovations later this year and expand into Asia-Pacific and Europe to support our customers’ global operations.”